Molecular Partners AG
MOLN
Rangering i aksjer
#19811
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Aksjekurs
$3.63
Markedsverdi
$138.99M
Endring (1 dag)
-1.64%
Endring (1 år)
1.69%
Land
CH
Handel Molecular Partners AG (MOLN)
Kategori
Healthcare
Inntekter for Molecular Partners AG (MOLN)
Inntekter i Oct 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Molecular Partners AG er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Molecular Partners AG fra 2013 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2025 | 0.00 | -100.00% |
| 2024 | $5.50M | -34.25% |
| 2023 | $8.37M | -95.92% |
| 2022 | $205.08M | 1,816.85% |
| 2021 | $10.70M | 2.85% |
| 2020 | $10.40M | -50.63% |
| 2019 | $21.07M | 100.17% |
| 2018 | $10.53M | -48.75% |
| 2017 | $20.54M | -9.28% |
| 2016 | $22.64M | -22.29% |
| 2015 | $29.13M | 8.69% |
| 2014 | $26.80M | -26.22% |
| 2013 | $36.33M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
